UK's NuCana Q4 net loss widens

Reuters03-20

UK's NuCana Q4 net loss widens

Overview

UK biopharma firm's Q4 net loss widened yr/yr
NuCana expects key clinical milestones for lead cancer drug NUC-7738 in 2026

Outlook

NuCana anticipates cash resources will fund operations into 2029

Result Drivers

NON-CASH FINANCE EXPENSE - Co said net loss for the year included £12.6 mln non-cash loss from fair value revaluation of warrants issued in May 2025 financing
HIGHER SHARE-BASED PAYMENTS - Co reported £10 mln in share-based payment expenses for the yr, up from £1.6 mln in 2024
INCREASED PROFESSIONAL FEES - Co incurred £1.4 mln in professional fees related to the issue of warrants in 2025

Company press release: ID:nGNX6gXFY6

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS		GBP 0
Q4 Net Income		-GBP 2.49 mln
Q4 Operating Income		-GBP 2.80 mln
Q4 Pretax Profit		-GBP 2.63 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620527956?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620527956","market":"fut","top_or_hot":-1,"title":"UK's NuCana Q4 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UK's NuCana Q4 net loss widens </title></head><body><p><span>Overview</span></p><ul><li><p>UK biopharma firm's Q4 net loss widened yr/yr</p></li><li><p>NuCana expects key clinical milestones for lead cancer drug NUC-7738 in 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>NuCana anticipates cash resources will fund operations into 2029</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NON-CASH FINANCE EXPENSE - Co said net loss for the year included £12.6 mln non-cash loss from fair value revaluation of warrants issued in May 2025 financing</p></li><li><p>HIGHER SHARE-BASED PAYMENTS - Co reported £10 mln in share-based payment expenses for the yr, up from £1.6 mln in 2024</p></li><li><p>INCREASED PROFESSIONAL FEES - Co incurred £1.4 mln in professional fees related to the issue of warrants in 2025</p></li></ul><p>Company press release: <span>ID:nGNX6gXFY6</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>GBP 0</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-GBP 2.49 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-GBP 2.80 mln</p></td><td></td></tr><tr><td><p>Q4 Pretax Profit</p></td><td></td><td><p>-GBP 2.63 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UK's NuCana Q4 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUK's NuCana Q4 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 04:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UK's NuCana Q4 net loss widens </title></head><body><p><span>Overview</span></p><ul><li><p>UK biopharma firm's Q4 net loss widened yr/yr</p></li><li><p>NuCana expects key clinical milestones for lead cancer drug NUC-7738 in 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>NuCana anticipates cash resources will fund operations into 2029</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NON-CASH FINANCE EXPENSE - Co said net loss for the year included £12.6 mln non-cash loss from fair value revaluation of warrants issued in May 2025 financing</p></li><li><p>HIGHER SHARE-BASED PAYMENTS - Co reported £10 mln in share-based payment expenses for the yr, up from £1.6 mln in 2024</p></li><li><p>INCREASED PROFESSIONAL FEES - Co incurred £1.4 mln in professional fees related to the issue of warrants in 2025</p></li></ul><p>Company press release: <span>ID:nGNX6gXFY6</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>GBP 0</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-GBP 2.49 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-GBP 2.80 mln</p></td><td></td></tr><tr><td><p>Q4 Pretax Profit</p></td><td></td><td><p>-GBP 2.63 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL1N4071FI:1","article_id":"2620527956","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620527956","pubTimestamp":1773951950,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UK's NuCana Q4 net loss widensOverviewUK biopharma firm's Q4 net loss widened yr/yrNuCana expects key clinical milestones for lead cancer drug NUC-7738 in 2026OutlookNuCana anticipates cash resources ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NCNA":"Nucana PLC"},"translate_title":"英国NuCana第四季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NCNA":0.9},"content_text":"UK's NuCana Q4 net loss widens OverviewUK biopharma firm's Q4 net loss widened yr/yrNuCana expects key clinical milestones for lead cancer drug NUC-7738 in 2026OutlookNuCana anticipates cash resources will fund operations into 2029Result DriversNON-CASH FINANCE EXPENSE - Co said net loss for the year included £12.6 mln non-cash loss from fair value revaluation of warrants issued in May 2025 financingHIGHER SHARE-BASED PAYMENTS - Co reported £10 mln in share-based payment expenses for the yr, up from £1.6 mln in 2024INCREASED PROFESSIONAL FEES - Co incurred £1.4 mln in professional fees related to the issue of warrants in 2025Company press release: ID:nGNX6gXFY6Key DetailsMetricBeat/MissActualConsensus EstimateQ4 EPSGBP 0Q4 Net Income-GBP 2.49 mlnQ4 Operating Income-GBP 2.80 mlnQ4 Pretax Profit-GBP 2.63 mlnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620527956","isCrawlerRequest":true}